High prevalence of GPRC5A germline mutations in BRCA1-mutant breast cancer patients

Anna Sokolenko, Daria Bulanova, Aglaya Iyevleva, Svetlana Aleksakhina, Elena Preobrazhenskaya, Alexandr Ivantsov, Ekatherina Kuligina, Natalia Mitiushkina, Evgeny Suspitsin, Grigoriy Yanus, Olga Zaitseva, Olga Yatsuk, Alexandr Togo, Poojitha Ojamies, Michael Dixon, Alexey Larionov, Sergey Kuznetsov, Evgeny Imyanitov

Research output: Contribution to journalArticleScientificpeer-review


In a search for new breast cancer (BC) predisposing genes, we performed a whole exome sequencing analysis using six patient samples of familial BC and identified a germline inactivating mutation c.183delG [p. Arg61fs] in an orphan G protein-coupled receptor GPRC5A. An extended case–control study revealed a tenfold enrichment for this mutation in BC patients carrying the 5382insC allele of BRCA1, the major founder mutation in the Russian population, compared to wild-type BRCA1 BC cases [6/117 (5.1%) vs. 8/1578 (0.5%), p = 0.0002]. In mammary tumors (n = 60), the mRNA expression of GPRC5A significantly correlated with that of BRCA1 (p = 0.00018). In addition, the amount of GPRC5A transcript was significantly lower in BC obtained from BRCA1 mutation carriers (n = 17) compared to noncarriers (n = 93) (p = 0.026). Accordingly, a siRNA-mediated knockdown of either BRCA1 or GPRC5A in the MDA-MB-231 human BC cell line reduced expression of GPRC5A or BRCA1, respectively. Knockdown of GPRC5A also attenuated radiation-induced BRCA1- and RAD51-containing nuclear DNA repair foci. Taken together, these data suggest that GPRC5A is a modifier of BC risk in BRCA1 mutation carriers and reveals a functional interaction of these genes.
Original languageEnglish
JournalInternational Journal of Cancer
Issue number10
Pages (from-to)2352-2358
Number of pages7
Publication statusPublished - 2014
MoE publication typeA1 Journal article-refereed

Fields of Science

  • 3122 Cancers

Cite this